A novel lectin from Agrocybe aegerita shows high binding selectivity for terminal N-acetylglucosamine by Jiang, Shuai et al.
Biochem. J. (2012) 443, 369–378 (Printed in Great Britain) doi:10.1042/BJ20112061 369
A novel lectin from Agrocybe aegerita shows high binding selectivity for
terminal N-acetylglucosamine
Shuai JIANG*, Yijie CHEN*, Man WANG*, Yalin YIN*, Yongfu PAN*, Bianli GU*, Guojun YU*, Yamu LI*,
Barry Hon Cheung WONG*, Yi LIANG† and Hui SUN*‡§1
*College of Life Sciences, Wuhan University, Wuhan 430072, People’s Republic of China, †Department of Clinical Immunology, Guangdong Medical College, Dongguan 523808,
People’s Republic of China, ‡Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (Wuhan University), Ministry of Education, Wuhan 430071, People’s Republic of China,
and §State Key Laboratory of Virology, Wuhan University, Wuhan 430072, People’s Republic of China
AnovellectinwasisolatedfromthemushroomAgrocybeaegerita
(designated AAL-2) by afﬁnity chromatography with GlcNAc
(N-acetylglucosamine)-coupled Sepharose 6B after ammonium
sulfate precipitation. The AAL-2 coding sequence (1224 bp)
was identiﬁed by performing a homologous search of the
ﬁve tryptic peptides identiﬁed by MS against the translated
transcriptome of A. aegerita. The molecular mass of AAL-2 was
calculated to be 43.175 kDa from MS, which was consistent
with the data calculated from the amino acid sequence. To
analyse the carbohydrate-binding properties of AAL-2, a glycan
array composed of 465 glycan candidates was employed, and
the result showed that AAL-2 bound with high selectivity to
terminal non-reducing GlcNAc residues, and further analysis
revealed that AAL-2 bound to terminal non-reducing GlcNAc
residueswithhigherafﬁnitythanpreviouslywell-knownGlcNAc-
binding lectins such as WGA (wheatgerm agglutinin) and GSL-
II (Griffonia simplicifolia lectin-II). ITC (isothermal titration
calorimetry) showed further that GlcNAc bound to AAL-2 in
a sequential manner with moderate afﬁnity. In the present study,
we also evaluated the anti-tumour activity of AAL-2. The results
showed that AAL-2 could bind to the surface of hepatoma cells,
leading to induced cell apoptosis in vitro. Furthermore, AAL-2
exerted an anti-hepatoma effect via inhibition of tumour growth
and prolongation of survival time of tumour-bearing mice in vivo.
Key words: Agrocybe aegerita, anti-hepatoma activity, fungal
lectin, glycan-binding property, N-acetylglucosamine.
INTRODUCTION
Changes in glycosylation patterns play important roles in
embryonic development, metabolic homoeostasis, pathogenic
infections, immune surveillance and various diseases, including
oncogenesis, diabetes and autoimmune disorders [1]. Therefore
glycan analysis is of great importance for understanding the
signiﬁcance of glycan modiﬁcations. Lectins, with their diverse
carbohydrate-binding properties, are potent tools for the study of
glycan conjugates in various biological materials without glycan
liberation.Forexample,lectinshavebeenappliedintheseparation
of cells at different stages, mitogenic activation of immune cells
and identiﬁcation of blood groups, as well as characterization of
glycan alterations on the surface between normal and neoplastic
cells [2–4].
The newly developed lectin array has been proved to be a
powerful tool for the comprehensive analysis of glycans or
glycoconjugates [5]. Much signiﬁcant information has been
obtained from use of lectin arrays. α1-2-Fucose-speciﬁc lectin
(rBC2LCN) has been applied in the detection of undifferentiated
induced pluripotent stem cells/embryonic stem cells, but not
differentiated somatic cells [6], TKA (Trichosanthes kirilowii
agglutinin) and PNA (peanut agglutinin) were used to distinguish
thestem-likeglioblastomaneurosphereculturedfromatraditional
adherent glioblastoma cell line [7], GNA (Galanthus nivalis
agglutinin), NPA (Narcissus pseudonarcissus agglutinin), PSA
(Pisum sativum agglutinin), LcH (Lens culinaris lectin) and
Con A (concanavalin A) have been used for the detection
of high-mannose N-linked oligosaccharides on differentiated
neutrophils in comparison with the promyelocytic leukaemia
cell line HL-60 [8], DSL (Datura stramonium lectin), SLL
[Solanum lycopersicum lectin; formerly LEL (Lycopersicon
esculentumlectin)]andMAL(Maackiaamurensislectin)showed
abindingpreferenceformouselaminin,whereasSNA(Sambucus
nigra agglutinin), SSA (Salvia sclarea agglutinin) and TJA-I
(Trichosanthes japonica agglutinin-I) showed strong binding to
bovine transferrin [9]. More lectins with unambiguous and/or
distinctive glycan-binding selectivity are needed to be studied
and exploited for probes of glycan structures. Thus there is an
urgent needto ﬁndpowerful lectin candidates for glycananalysis.
Lectinsareusefultoolsfortumourdiagnosis,antivirusresearch
and drug-delivery studies [10]. For example, MAL has been used
in prostate cancer diagnosis because of its preferential binding
to prostate-speciﬁc antigen [11], HPA (Helix pomatia agglutinin)
recognizes the glycosylation changes of metastatic breast cancer
[12], BCA (Boodlea coacta lectin) can potently provide entry
inhibition of HIV-1 and inﬂuenza viruses [13], microvirin has
anti-HIV-1 activity with a high safety proﬁle and low toxicity
[14], and odorranalectin has been reported to be the smallest
lectin so far and with potential for drug delivery and targeting
Abbreviations used: AAL-2, Agrocybe aegerita lectin 2; BLL, Boletopsis leucomelas lectin; GlcNAc, N-acetylglucosamine; GSL-II, Griffonia simplicifolia
lectin-II; HPA, Helix pomatia agglutinin; IPTG, isopropyl β-D-thiogalactopyranoside; ITC, isothermal titration calorimetry; LacNAc, N-acetyl-lactosamine;
MAL, Maackia amurensis lectin; MALDI, matrix-assisted laser-desorption ionization; MS/MS, tandem MS; nAAL-2, native AAL-2; ORF, open reading frame;
PI, propidium iodide; PVL, Psathyrella velutina lectin; rAAL-2, recombinant AAL-2; RFU, relative ﬂuorescence units; SLL, Solanum lycopersicum lectin;
TBS, Tris-buffered saline; TOF, time-of-ﬂight; WGA, wheatgerm agglutinin.
The nucleotide sequence data for Agrocybe aegerita lectin 2 will appear in the GenBank®, EMBL, DDBJ and GSDB Nucleotide Sequence Databases
under accession number JN001164.
The glycan array data of AAL-2 were deposited in the Consortium for FunctionalGlycomicsdatabase with the labels primscreen_3312–primscreen_3315.
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[15]. An increasing number of lectins from plants and animals
have been puriﬁed and characterized; however, the information
on lectins isolated from fungal sources remains limited [16].
Fungal lectins are attractive because of their wide distribution,
high content, varied carbohydrate-binding speciﬁcities and
especially anti-tumour activities. Agaricus bisporus lectin was
showntopossessanti-tumouractivityagainsthumancoloncancer
HT29 and breast cancer cell lines MCF-7 [17], Russula lepida
lectin exhibited anti-proliferative activity in hepatoma HepG2
cells and human breast cancer MCF-7 cells [18], Tricholoma
mongolicum lectin-1 and lectin-2 could inhibit the growth of
sarcoma 180 cells [19], Pleurotus citrinopileatus lectin exerted
potent anti-tumour activity in mice bearing sarcoma 180 [20],
and Grifola frondosa lectin was shown to be cytotoxic to HeLa
cells [21].
In the present paper, we report a novel fungal lectin AAL-
2( Agrocybe aegerita lectin 2) from the fruiting body of A.
aegerita. A glycan array analysis showed that AAL-2 bound
to non-reducing GlcNAc (N-acetylglucosamine) termini with
high selectivity, even higher than the previously well-known
GlcNAc-binding lectins WGA (wheatgerm agglutinin) and GSL-
II (Griffonia simplicifolia lectin-II), which have been widely
used in biochemical and biomedical research. Moreover, we
showed that AAL-2 had anti-tumour activity not only for the
induction of hepatoma cells apoptosis in vitro,b u ta l s of o r
the inhibition of H22 hepatoma growth and prolongation of
survival times of tumour-bearing mice in vivo. The cloning and
prokaryotic/bacterialproteinexpressionofAAL-2providedclues
to the deep investigation of the glycan-binding mechanism of
AAL-2 and further application of AAL-2 in probing GlcNAc-
related glycans or glycoconjugates.
EXPERIMENTAL
Chemicals and reagents
TheediblemushroomA.aegeritawascollectedfromtheSanming
Institute of Fungi (Sanming, Fujian, P.R. China). GlcNAc was
purchased from Sangon Biotech. Epoxy-activated Sepharose 6B
was purchased from GE Healthcare.
Cell lines and mice
A murine hepatoma cell line H22, and a human hepatoma cell
line Huh7, were provided by the CCTCC (China Center for
Type Culture Collection, Wuhan University). Male BALB/c mice
(6–8-week-old) were purchased from the Hubei Experimental
Animal Laboratory(Hubei,China)andmaintainedinapathogen-
free facility. Procedures were performed according to approved
protocolsandinaccordancewithrecommendationsfortheproper
care and use of laboratory animals.
Preparation of GlcNAc-coupled Sepharose 6B matrix
GlcNAc-coupled Sepharose 6B was prepared according to the
manufacturer’s instructions (GE Healthcare). In brief, 2 g of
epoxy-activated Sepharose 6B was washed twice with 200 ml
of distilled water, mixed with GlcNAc at a ﬁnal concentration of
200 μmol/ml in distilled water (pH 13) at a temperature of 30◦C
for 15 h. Free remaining groups were blocked by incubating in
1 M ethanolamine, and the mixture was gently agitated at 45◦C
for 4 h. The Sepharose 6B-coupled GlcNAc matrix was washed
extensively with TBS (Tris-buffered saline) (pH 7.2) and packed
into an empty 100-mm-long glass column with a 10 mm inner
diameter. The column was stored at 4◦C until use.
Puriﬁcation of AAL-2 from mushroom A. aegerita
Dried A. aegerita fruiting bodies were crushed into a powder, and
50 g of the dried mass was dissolved and extracted three times
with1 litreofdistilledwaterat4◦C.Theextractswerepooledand
centrifuged at 10000 g for 15 min. Solid ammonium sulfate was
added to the supernatant to 40% saturation and centrifuged again
at 10000 g for 15 min. Solid ammonium sulfate was then added
to the supernatant to obtain 80% saturation, and the 40–80%
precipitate was collected by centrifugation at 10000 g for 15 min.
The precipitated protein was dissolved in 200 ml of distilled
water and dialysed extensively against 50 mM TBS (pH 7.2) by
changing the dialysis buffer three times at 4◦C overnight. The
sample was loaded on to an afﬁnity column (GlcNAc-coupled
Sepharose 6B matrix) pre-equilibrated with TBS (pH 7.2), and
elutedwith0.2 MGlcNAcin50 mMTBS(pH 7.2)afterextensive
washing with TBS. The enriched AAL-2 fraction was stored at
−20◦C.
SDS/PAGEwasperformedwitha15%acrylamiderunninggel
and5%stackinggel.ProteinbandswereidentiﬁedbyCoomassie
Brilliant Blue R-250 staining.
Preparation of tryptic peptides and peptide sequencing
ThebandcorrespondingtoAAL-2wasexcisedfromaCoomassie
Brilliant Blue-stained SDS/polyacrylamide gel and tryptically
digested according to standard protocols. The peptides were
derivatized for the N-terminus with SPITC (4-sulfophenyl
isothiocyanate) and desalted with ZipTip
TM. MALDI (matrix-
assisted laser-desorption ionization)–MS was performed on
a 4700-Proteomics Analyzer (Applied Biosystems) and PSD
(power spectral density) spectra were collected with 3000 laser
shots at 1 keV collision energy without CID (collision-induced
dissociation). MS data were analysed by PMF (peptide mass
ﬁngerprinting) using MASCOT software.
Molecular mass determination by MS
MALDI–TOF (time-of-ﬂight) mass spectra were obtained using
a Voyager-RP mass spectrometer (PerSeptive Biosystems) [22].
cDNA cloning of AAL-2 and expression of rAAL-2 (recombinant
AAL-2) in Escherichia coli
Total RNA was prepared from the fresh fruiting bodies
of A. aegerita by grinding in liquid nitrogen followed by
extraction with Plant RNA Isolation Reagent (BioTeke). Full-
length cDNAs were synthesized from 1 μg of total RNA using
MMLV (Moloney murine leukaemia virus) reverse transcriptase
(Promega) after RQ1 RNase-free DNase digestion (Promega)
according to the manufacturer’s instructions. Nested PCR was
applied to amplify the AAL-2 coding sequence, and two pairs
of primers were designed as follows: forward external primer
aal-2_5
 _F1,5
 -ATGAACGTGAACGTGGGAGG-3
 ;re verseex-
ternal primer aal-2_3
 _R1, 5
 -CTAGTAATCCGTGCGAGTCG-
3
 ; forward ORF (open reading frame) primer aal-2_5
 _F2,
5
 -ATGACCAGCAACGTCATCAC-3
 ; reverse ORF primer
aal-2_3
 _R2, 5
 -ATGCCTGCTGCTGTCCAAGT-3
 .P C Rw a s
performed using Taq DNA polymerase (Promega) with the
following temperature proﬁle: 5 min at 95◦C, 30 s at 94◦C
a n d3 m i na t7 2 ◦C, for 35 cycles. The ampliﬁed product
obtained with external primers was used as the template for
a second round of ampliﬁcation with the ORF primers. The
puriﬁed PCR fragment was cloned into the pET-30a vector
(Novagen) according to the manufacturer’s instructions. The
resulting plasmid containing rAAL-2 coding sequence was used
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fortransformationintoE.coliBL21cells(Novagen).Inductionof
protein expression was performed with 1 mM IPTG (isopropyl β-
D-thiogalactopyranoside) at mid-exponential phase (D600 of 0.4–
0.6), and the bacteria were grown for an additional 5 h at 37◦C
withshakingat220 rev./min.Thebacteriawerethenharvestedand
lysed. The supernatant was loaded on to a GlcNAc–Sepharose 6B
column, and rAAL-2 was puriﬁed by GlcNAc-coupled Sepharose
6B afﬁnity chromatography as described above.
Biotinylation of AAL-2
To biotinylate AAL-2, puriﬁed AAL-2 (200 μgi n2 5 0μlo fP B S )
was mixed with 400 μl of biotin ester solution (100 μg of biotin
ester/200 μg of lectin) and left for 30 min at room temperature
(24◦C).Thebiotin-labelledAAL-2wascollectedusingSephadex
G-250 and stored at −20◦C until use.
Glycan array analysis
To determine the carbohydrate-binding speciﬁcity of AAL-2,
glycan array analysis was performed by the Consortium for
Functional Glycomics (Core H; http://www.functionalglycomics.
org/static/consortium/resources/resourcecoreh.shtml). The prin-
ted glycan array (Mammalian Printed Array version 4.1) [23]
was composed of 465 different natural and synthetic mammalian
glycans. In the binding assay, array slides, containing six
replicates per glycan or glycoconjugate, were incubated with
different concentrations of biotinylated AAL-2 (0.1, 1, 50 and
200 μg/ml). The slides were then washed, and bound lectin was
detected using ﬂuorescently labelled streptavidin. Array slides
were subjected to imaging, and the ﬂuorescence was measured
as described previously [24]. Brieﬂy, ﬂuorescence intensity was
detectedusingaScanArray5000confocalscanner(PerkinElmer).
ImaGene® image analysis software (BioDiscovery) was used to
analyse the image. The relative binding for each glycan was
expressed as mean RFU (relative ﬂuorescence units) of four of
the six replicates.
ITC (isothermal titration calorimetry)
ITC experiments on the interaction of GlcNAc with AAL-2
were performed at 25◦C with a VP-ITC isothermal titration
calorimeter (Microcal). Freshly puriﬁed AAL-2 was dialysed
overnight in PBS (pH 7.2) at 4◦C. The protein concentration
in the microcalorimeter cell (1.4478 ml volume) was 50 μM.
GlcNAc solution was made up to 7 mM in PBS and placed in the
syringe. The ﬁrst injection (4 μl) was followed by 27 injections
of 10 μl, and the stirring rate was set at 300 rev./min. The dilution
heat of the GlcNAc was measured by injecting GlcNAc
solution into buffer alone and was subtracted from the
experimental curves before data analysis. The experimental data
were ﬁtted to a theoretical titration curve using Microcal Origin
software supplied with the instrument, and the standard molar
enthalpy change for the binding,  bHm
0, and the dissociation
constant, Kd,w e r ed e r i v e d .T h es t a n d a r dm o l a rf r e ee n e r g y
change,  bGm
0, and the standard molar entropy change,  bSm
0,
for the binding reaction were calculated by using the following
thermodynamic equations:
 bGm
0 = RT · InKd (1)
 bSm
0 =

 bHm
0 −  bGm
0
/T (2)
Haemagglutination assay
The haemagglutination activity of puriﬁed lectin was determined
as described previously [25]. Brieﬂy, the haemagglutination
activity assay was performed on a microtitre plate, and the lectin
sample (50 μl, 1 mg/ml) was serially diluted with PBS and mixed
with 50 μlo fa2 % suspension of chicken red blood cells at
room temperature. Measurements were taken after 30 min when
the control (no lectin added) was fully precipitated.
The effects of metal cations on the haemagglutination activity
ofAAL-2weredeterminedintheabsenceandpresenceof10 mM
Ca
2+,Z n
2+,M n
2+ or Mg
2+ after dialysis against 20 mM EDTA.
The effect of temperature on lectin stability was monitored over
a temperature range by incubation with AAL-2 for 30 min at
each temperature. The samples were then cooled rapidly and
assayed for haemagglutination activity. The effect of pH on lectin
stability was determined by incubating with AAL-2 with buffers
of different pHs for 30 min, and haemagglutination activity was
determined after neutralization.
Preparation of a polyclonal anti-AAL-2 antibody
A rabbit polyclonal antibody against AAL-2 was prepared as
reported previously [26]. Brieﬂy, 500 μg of nAAL-2 (native
AAL-2) in 500 μl of PBS was emulsiﬁed with 500 μlo f
complete Freund’s adjuvant (Sigma). The emulsion was injected
into 6-month-old New Zealand White rabbits by multipoint
subcutaneous implantation. The second and third inoculations
were performed on days 24 and 36 with Freund’s incomplete
adjuvant (Sigma), and the fourth inoculation was performed
on day 41 without any adjuvant. At 1 week after the ﬁnal
immunization, sera were separated from the collected blood
samples and antibody against nAAL-2 was detected by ELISA.
Cell culture
H22 cells and Huh7 cells were cultured in RPMI 1640 medium
and DMEM (Dulbecco’s modiﬁed Eagle’s medium) respectively.
Cell culture media were supplemented with 10% (v/v) heat-
inactivated (56◦C, 30 min) FBS (fetal bovine serum), 5 units/ml
penicillin and 50 μg/ml streptomycin. All cells were maintained
at 37◦C in a humidiﬁed atmosphere containing 5% CO2.F o ra l l
experiments, cells were plated 2 h before treatment to allow for
adherence.
Cell-adhesion assay, Annexin V/PI (propidium iodide) staining and
FACS analysis
In the cell-adhesion assay, H22 and Huh7 cells were incubated
withorwithoutAAL-2,andthenwithpolyclonalantibodyagainst
AAL-2 and FITC-conjugated goat anti-rabbit IgG. For Annexin
V/PI staining, H22 and Huh7 cells were treated with AAL-2 at
ﬁnal concentrations of 0, 0.6, 1.2 or 2.4 μM for 24 and 36 h
respectively. The cells were collected, washed twice with ice-
cold PBS (pH 7.4), and stained using an Annexin V/PI apoptosis
kit (MultiScience Biotech). The samples were mixed gently
and incubated in the dark. All samples were analysed by ﬂow
cytometry (Beckman, Epics Altra)
Subcutaneous tumour models
H22 cells (10
7) in 100 μl of PBS were subcutaneously injected
into the right ﬂank of BALB/c mice. At days 7, 9, 11, 13, 15, 17
and 19 after tumour inoculation, mice were injected at the tumour
site with 5 mg of AAL-2/kg in 100 μl of PBS or diluent control.
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Figure 1 Puriﬁcation of AAL-2 and the amino acid sequences of tryptic
peptides identiﬁed by MS
(A) Crude extract was applied to a GlcNAc monomer-coupled epoxy-activated Sepharose 6B
column (1cm×10cm) and equilibrated with TBS (pH7.2). After washing with TBS, AAL-2 was
eluted with TBS containing 0.2M GlcNAc (indicated by the arrow). The plot was generated by
¨ AKTAprime(GEHealthcare).(B)SDS/polyacrylamidegelofAAL-2wasstainedwithCoomassie
Brilliant Blue. Molecular masses are indicated in kDa.(C) Aminoacid sequencedatafor AAL-2.
The ﬁve tryptic peptides identiﬁed by MS/MS are shown.
Tumour volume (V) was determined by caliper measurements
(V=L×W
2/2), where L is length and W is width.
Statistical analysis
The two-sample Student’s t test was used for comparisons
between groups. Statistical analysis was performed with
GraphPad Prism 5 software. Results are means+ −S.E.M., and
statistical signiﬁcance was deﬁned as P<0.05.
RESULTS
Puriﬁcation of AAL-2 and the determination of the amino acid
sequences from AAL-2 tryptic peptides
Total crude proteins were extracted from dried A. aegerita
fruiting bodies by water-extraction, 40–80% ammonium sulfate
precipitation and dialysis against TBS. The total crude proteins
were loaded on to the GlcNAc-coupled Sepharose 6B column
and eluted with 0.2 M GlcNAc after extensive TBS washing
(Figure 1A). A total fraction of 6 ml of eluate (48–54 ml) was
collected. Representative puriﬁcation fractions from the afﬁnity
chromatographic column were separated by SDS/PAGE in the
presence of 2-mercaptoethanol. The eluate fraction yielded a
single band (approximately 43 kDa) and was named AAL-
2 (Figure 1B). AAL-2 was characterized further using de
novo sequencing by MS/MS (tandem MS), and ﬁve tryptic
peptides were identiﬁed (Figure 1C). The ﬁve peptide sequences
were analysed further by BLASTP at NCBI (http://www.ncbi.
nlm.nih.gov/BLAST), and only two peptides (labelled #1 and
#3) showed homology with the GlcNAc-binding lectin PVL
(Psathyrella velutina lectin) [27] (results not shown).
Identiﬁcation of the AAL-2 coding sequence
To determine the coding sequence of AAL-2, the A. aegerita
transcriptome was sequenced. Raw Illumina sequencing data of
the A. aegerita transcriptome was deposited in the Sequence
Figure 2 Identiﬁcation of AAL-2 coding sequence
(A) The AAL-2 coding sequence is located on the complementary strand of UniGene 4198. (B) The AAL-2 coding sequence consists of 1224bp, which is computationally translated into 407 amino
acids. The deduced amino acid sequence is shown under the AAL-2 coding sequence, and the ﬁve tryptic peptides (underlined) of AAL-2 identiﬁed by MS are aligned under the deduced amino acid
sequence. MALDI–TOF/TOF analysis revealed 69% sequence coverage of the full-length AAL-2 (grey box). The initiation codon ATG is boxed and the stop codon tag is marked with an asterisk.
(C) Determination of AAL-2 molecular mass by MALDI–TOF-MS to be 43175.72 Da. Intens., intensity (in arbitrary units, a.u.).
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Figure 3 Cloning, expression and puriﬁcation of AAL-2
(A) Total RNA was isolated from fresh A. aegerita fruiting body and ampliﬁed by reverse
transcription–PCR. The AAL-2 coding sequence (∼1.2kb) was ampliﬁed by nested PCR.
(B) The AAL-2 coding sequence was cloned into pET-30a plasmids followed by transformation
into E. coli BL21 cells. A strong band appeared at approximately 43 kDa after IPTG-induction
for 5 h compared with non-induction. (C) nAAL-2 and rAAL-2 showed the same electrophoretic
mobility on SDS/PAGE and shared the same immunogenicity after immunoblotting with the
anti-nAAL-2 polyclonal antibody. Molecular masses are indicated in kDa.
Read Archive at NCBI (accession number SRA026731.1). The
ﬁve tryptic AAL-2 peptides were searched for similarity against
the A. aegerita transcriptome by BLASTX. The ORF of the
complementary strand of UniGene 4198 was analysed, and
a fragment containing 1224 bp was identiﬁed and labelled
as the AAL-2 coding sequence (Figures 2A and 2B). Five
tryptic peptides (underlined) from AAL-2 showed full homology
with the protein translated from the identiﬁed AAL-2 coding
sequence, with the latter MALDI–TOF/TOF analysis showing
69% coverage (Figure 2B, grey box); moreover, the molecular
mass was calculated to be 43175 Da by the ExPASy Proteomics
Server (http://www.expasy.org/tools), and was consistent with
the AAL-2 mass (43175.72 Da) identiﬁed by MALDI–TOF-MS
(Figure 2C). The isoelectric point of AAL-2 was calculated to be
8.19 by ExPASy.
Cloning of AAL-2 coding sequence and rAAL-2 protein expression
TheAAL-2codingsequencewassuccessfullyclonedafternested
PCR using total cDNA as a template (Figure 3A). The nucleotide
sequenceoftheclonedAAL-2codingsequencewasfullyidentical
with that from the A. aegerita transcriptome. The AAL-2 coding
sequencewasthenclonedintotheexpressionvectorpET-30a,and
the resulting plasmid was used for the transformation of E. coli
BL21 cells. The bacteria were grown to mid-exponential phase
(D600 of 0.4–0.6) and then induced with 1 mM IPTG. After 5 h of
induction, the lysate of the bacteria was separated by SDS/PAGE,
and a strong band of approximately 43 kDa appeared compared
with non-induced bacteria (Figure 3B). The supernatant fractions
from the lysate were loaded on to the GlcNAc-coupled Sepharose
6B column. rAAL-2 was eluted as a single symmetrical peak at
the same elution volume as nAAL-2 (results not shown), and
produced an electrophoretic mobility by SDS/PAGE identical
with that of nAAL-2 at approximately 43 kDa. In addition,
polyclonal antibody raised against nAAL-2 was able to detect
rAAL-2, and a precipitin band was formed identical with that of
nAAL-2 (Figure 3C).
Analysis of the carbohydrate-binding properties of AAL-2
characterized by glycan array and ITC
The puriﬁcation of AAL-2 by afﬁnity chromatography showed
that AAL-2 was able to bind to GlcNAc. To characterize further
Figure 4 Binding properties of AAL-2 for GlcNAc assessed by glycan array analysis and ITC proﬁling
AAL-2-bindingspeciﬁcitywasdeterminedbyglycan screeningonaprinted array(Version4.1 oftheConsortiumforFunctionalGlycomics).(A)Upperpanel:thetopten glycanswithhighestbinding
afﬁnity to AAL-2 (200μg/ml). The binding glycan GlcNAc is shown and labelled with a red asterisk. Results are means+ −S.E.M. The glycan number at the bottom indicates the various glycans
usedintheglycanarray.Theentireglycanarrayisavailableathttp://www.functionalglycomics.org/static/consortium/resources/resourcecoreh14.shtml.Lowerpanel:theheatmapshowsthebinding
selectivity of AAL-2 at different concentrations (0.5, 1, 50 and 200μg/ml). The log (base 2) of RFU values is represented on the bar on the right-hand side. Warmer colours indicate higher
binding afﬁnity. (B) ITC results for GlcNAc monomer (7 mM) binding to AAL-2 (0.05mM) in PBS at 25◦C. Upper panel: data obtained from 28 automatic injections of 10μl of GlcNAc monomer
each into the AAL-2-containing cell. Lower panel: plot of the total heat released as a function of ligand concentration for the titration shown above (squares). The continuous line represented the best
least-squares ﬁt to the obtained data. All thermodynamic measurements of AAL-2 binding to GlcNAc were performed at 25◦C.
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the glycan-binding proﬁle of AAL-2, glycan array analysis
was performed by testing the binding afﬁnity of AAL-2 to
465 glycan candidates. The glycan array was performed at
different concentrations (0.1, 1, 50 and 200 μg/ml) of AAL-2,
and the binding glycans with more than 5000 RFU were listed
according to the glycan-binding proﬁle of AAL-2 at 200 μg/ml
(Supplementary Table S1 at http://www.BiochemJ.org/bj/443/
bj4430369add.htm). The results showed that the binding selectiv-
ity changed little with a wide concentration range (Figure 4A,
lower panel). Almost all of the top 30 glycans in the binding pro-
ﬁles possessed terminal non-reducing GlcNAc (Figure 4A, upper
panel, and Supplementary Figure S1 at http://www.BiochemJ.
org/bj/443/bj4430369add.htm). In addition, Gal (galactose)–
GlcNAc [LacNAc (N-acetyl-lactosamine)] linked behind would
increase the binding afﬁnity to the terminal GlcNAc, and the
glycan GlcNAc-(LacNAc)3 exhibited the highest binding afﬁnity
among the 465 glycan candidates (Figure 4A, upper panel).
However, (LacNAc)3, with the absence of the terminal GlcNAc
compared with GlcNAc-(LacNAc)3, showed signiﬁcantly low
bindingafﬁnity.IncomparisonwithotherGlcNAc-bindinglectins
(Figure5),AAL-2performedbetterthanthewell-knownGlcNAc-
binding lectins WGA and GSL-II, which have been used widely
in glycan studies for their high GlcNAc-binding selectivity.
Therefore AAL-2 can be deﬁned as a lectin with high binding
selectivity to glycans with non-reducing GlcNAc termini and has
potential in GlcNAc-related glycan or glycoconjugate analysis.
ITC was also performed in order to thermodynamically
characterize the GlcNAc and AAL-2 interactions. Figure 4(B)
(upperpanel)showstherawITCcurveresultingfromtheinjection
of GlcNAc into a solution of AAL-2. The titration curve showed
that GlcNAc binding to AAL-2 was exothermic, resulting in
negative peaks in the plots of power against time. Figure 4(B)
(lower panel) shows the plot of the heat evolved per mol of
GlcNAc added, with the heat of GlcNAc dilution subtracted. Our
calorimetricdatawereﬁttedtoasequentialbindingmodel,andthe
thermodynamic parameters for the binding of GlcNAc to AAL-2
are summarized in Table 1. The values of Kd1 and Kd2 are 195
and 459 μM respectively, which indicates that GlcNAc bound to
AAL-2 with moderate binding afﬁnity.
AAL-2 can induce apoptosis in hepatoma cells in vitro
AAL-2 could bind to H22 and Huh7 hepatoma cells (Figures 6A
and6B)andinduceapoptosisofH22cellsandHuh7cellsinvitro.
Table 1 Thermodynamic parameters for the binding of AAL-2 to GlcNAc as
determined by ITC
Thermodynamic parameters, Kd and  bHm
0, were determined by using the sequential binding
sites model. The standard molar binding free energy ( bGm
0) and the standard molar binding
entropy ( bSm
0) for the binding reaction were calculated using eqns (1) and (2) respectively.
The buffer used in the assay was PBS (pH7.2), ITC measurements was performed at 25◦C.
Results are means+ −S.E.M. 1 cal=4.184 J.
Thermodynamic parameter (unit) Value
Ka1 (103 M−1)5 . 1 3 + −0.36
Ka2 (103 M−1)2 . 1 8 + −0.06
Kd1 (μM) 194.93+ −70.16
Kd2 (μM) 458.72+ −27.52
 bHm1
0 (kcal·mol−1) −32.22+ −1.91
 bHm2
0 (kcal·mol−1) −31.69+ −2.24
 bGm1
0 (kcal·mol−1) −5.06+ −0.21
 bGm2
0 (kcal·mol−1) −4.56+ −0.04
 bSm1
0 (cal·mol·1 ·K−1) −91.08+ −1.92
 bSm2
0 (cal·mol−1 ·K−1) −91.01+ −2.24
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Figure 6 AAL-2 induces apoptosis in hepatoma cells in vitro
AAL-2 could bind to H22 (A) and Huh7 (B) hepatoma cells. H22 cells and Huh7 cells were untreated (green histograms), incubated with the anti-AAL-2 antibody alone (pink histograms), or with
both AAL-2 and anti-AAL-2 antibody (blue histograms), and analysed by ﬂow cytometry. The mean ﬂuorescence intensity (MFI) values of the different incubation conditions are indicated in each
histogram. Apoptotic H22 (C) and Huh7 (E) cells were detected by Annexin V/PI staining after 24 and 36h of incubation respectively with different concentrations of AAL-2. The percentages of
pro-apoptotic H22 cells (D) and Huh7 cells (F) gated on Annexin V+/PI− were calculated. Results are means+ −S.E.M. (n=3); *P <0.05, **P <0.01, ***P <0.001.
The amount of apoptosis of H22 cells was 1.8% after 24 h of
culture, and increased signiﬁcantly to 4.4%,6 . 3 % and 10%
at ﬁnal concentrations of 0.6, 1.2 and 2.4 μM respectively
(Figures 6C and 6D). Similarly, the proportion of apoptotic Huh7
cellswas4.7%,andincreasedto7.1%,13.3%and36.3%when
treated with AAL-2 at ﬁnal concentrations of 0.6, 1.2 and 2.4 μM
respectively for 36 h (Figures 6E and 6F). The results indicate
that AAL-2 induced cell apoptosis in a concentration-dependent
manner.
AAL-2 can inhibit hepatoma growth and extend the survival time of
tumour-bearing mice in vivo
The anti-hepatoma activity of AAL-2 was investigated further
by using a mouse model of H22 hepatocellular carcinoma. Mice
treated with AAL-2 showed a signiﬁcant reduction in tumour
volume (Figure 7B), whereas body weight remained unaltered
(Figure 7A) compared with control mice treated with PBS. In
addition, AAL-2 treatment was able to extend the survival time
of tumour-bearing mice (Figure 7C). Overall, we conclude that
AAL-2 has anti-hepatoma activity by inhibiting hepatocellular
carcinoma growth and can extend survival times of tumour-
bearing mice.
DISCUSSION
A. aegerita is one of the most cultivated mushrooms in China, and
has been highly valued as a functional food for its anti-tumour
and nutritional beneﬁts [28]. We have previously puriﬁed AAL
(A. aegerita lectin) from A. aegerita, which showed extensive
anti-tumour activity owing to speciﬁc binding to the Thomsen–
Friedenreich disaccharide tumour antigen and subsequently
resulted in tumour cell apoptosis [29,30]. In the present study, a
novel fungal lectin AAL-2 was puriﬁed from A. aegerita by using
one-step afﬁnity chromatography. AAL-2 showed high binding
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Figure 7 AAL-2 inhibits hepatocellular carcinoma growth and prolongs
survival time of tumour-bearing mice in vivo
A total of 107 H22 cells were injected subcutaneously into the right ﬂank of BALB/c mice. On
days 7, 9, 11, 13, 15, 17 and 19 after tumour inoculation, mice were injected at the tumour site
with 5 mg of AAL-2/kg in 100μl of PBS or diluent control. Tumour-bearing mice treated with
AAL-2andPBSweremonitoredforchangesinbodyweight(A),tumourgrowth(B)andsurvival
time (C). Results are means+ −S.D. (n=10); *P <0.05.
selectivity to glycans with a non-reducing GlcNAc terminus,
and the binding afﬁnity increased when one or more LacNAc
disaccharides were linked to the terminal GlcNAc via α1-3,
α1-4 or β1-3, β1-4 linkages to form a GlcNAc-(LacNAc)1–3
structure, implying that the addition of a LacNAc could increase
the binding afﬁnity to terminal GlcNAc (Supplementary Table
S1). The glycan GlcNAc-(LacNAc)3 represented the highest
binding afﬁnity among the 465 candidates; however, the
high binding afﬁnity would be lost if the terminal GlcNAc was
removed. In addition, the binding selectivity changed little at a
wide concentration range of AAL-2, indicating that the glycan-
bindingactivityofAAL-2washighlyselective,lownoiseandwas
not affected by the high concentration (200 μg/ml) (Figure 4A,
lower panel).
Our glycan array analysis revealed that AAL-2 bound to
terminal GlcNAc with high selectivity. We then compared
further the glycan-binding speciﬁcity of AAL-2 with that
of other GlcNAc-binding lectins: PVL, BLL (Boletopsis
leucomelas lectin), GSL-II, WGA, HPA and SLL. The
GlcNAc-binding speciﬁcity of PVL was determined by afﬁnity
chromatography,andPVLwasshowntohavepreferentialbinding
to oligosaccharides bearing non-reducing terminal β-GlcNAc
linked 1-6 or 1-3, but poor afﬁnity for 1-4 linkages [27], whereas
AAL-2 bound preferentially to oligosaccharides bearing a non-
reducing terminal β-GlcNAc linked via a 1-4 or 1-3, rather than
a 1-6, linkage. The unique structure of carbohydrate-binding
domains might contribute to the binding preference of AAL-2
to terminal β-GlcNAc-linked oligosaccharides; our future studies
will focus on the analysis of the carbohydrate–lectin interactions
via crystallization of the AAL-2 and GlcNAc complex. The
GlcNAc-binding speciﬁcity of BLL was determined by frontal
afﬁnity chromatography, and BLL was shown to have high
binding afﬁnity for mono-, bi- and tri-antennary agalactosylated
glycans [31], whereas AAL-2 showed high binding afﬁnity for
mono-terminal non-reducing GlcNAc residues. Other GlcNAc-
binding lectins, i.e. GSL-II, WGA, HPA and SLL, with their
top ﬁve highest binding glycans from the glycan array data are
listed in Figure 5. The comparative analysis showed that AAL-
2 and GSL-II had the highest binding selectivity for terminal
GlcNAc, whereas AAL-2 showed even higher binding selectivity
than did GSL-II, a well known and widely studied lectin for
the recognition of terminal GlcNAc residues. Moreover, AAL-
2 binds to glycans in a metal-ion-independent manner, whereas
Ca
2+ is required for GSL-II-binding activity (results not shown).
The binding activity of AAL-2 was stable under 70◦Ca n d
within the pH range 6.0–11.0 (Supplementary Figure S2 at
http://www.BiochemJ.org/bj/443/bj4430369add.htm). We com-
pared further the amino acid sequences of AAL-2, GSL-II, WGA
and HPA. Surprisingly, amino acid sequences of these GlcNAc-
binding lectins showedlow similarity to eachother, although they
shared similar glycan-binding properties (Supplementary Fig-
ure S3 at http://www.BiochemJ.org/bj/443/bj4430369add.htm).
AAL-2,althoughnewlydiscovered,hasthepotentialtobeutilized
as a molecular probe to detect terminal GlcNAc sugars with high
binding selectivity in glycan analysis.
Polylactosamine has been reported to be present on the
immune co-stimulatory molecules CD28 and CD19. In a
previous study [32], B-cells, T-cells and macrophages in the
absence of polylactosamines were found to be hypersensitive
to stimulation, and SLL was used in the detection of the
polylactosamines with at least three lactosamine unit repeats
[(LacNAc)n>3] [32]. By using glycan arrays to detect the binding
proﬁle of lectins, SLL showed high binding selectivity for
Neu5Ac (N-acetylneuraminic acid)/Fuc (fucose)-(LacNAc)3 and
(LacNAc)3 (Consortium for Functional Glycomics database:
primscreen_PA_v2_711_09262005). In the present study, the
glycan array data showed that AAL-2 bound to GlcNAc-
(LacNAc)3 with the highest afﬁnity among the 465 glycan
candidates, indicating that AAL-2 recognized polylactosamine
(LacNAc)3 with a terminal GlcNAc modiﬁcation. Overall, the
results imply that AAL-2 and SLL would form pairs of com-
plementary probes to monitor changes and modiﬁcations of
polylactosamine.
GlcNAc has been reported to be aberrantly expressed in several
carcinomas, resulting in increased levels and abnormal types of
GlcNAc on the cell surface [33,34]. The present study suggests
that AAL-2, with high binding selectivity to GlcNAc, could bind
tohepatomacellsandinducecellapoptosis.Thisbindingproperty
probably endowed AAL-2 with binding priority to those tumour
cells, therefore leading to its potential applications for cancer
diagnosis.
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Table S1 Carbohydrate-binding proﬁles of AAL-2 determined by glycan array analysis
The Table lists the glycans present on the glycan array (Consortium for Functional Glycomics). The carbohydrate-binding proﬁles of AAL-2 at different concentrations (0.1, 1, 50 and 200μg/ml)
are shown. The glycans binding with more than 5000 RFU are listed according to the glycan-binding proﬁle of AAL-2 at 200μg/ml. Average RFU represents the degree of binding of ﬂuorescently
labelled streptavidin to biotin-labelled AAL-2.
Average RFU for AAL-2 at
Order Glycan number Glycan structure 200μg/ml 50μg/ml 1μg/ml 0.1μg/ml
1 336 GlcNAcα1-4Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 30519 13453 1496 226
2 171 GlcNAcα1-3Galβ1-4GlcNAcβ-Sp8 24487 8139 898 130
3 175 GlcNAcβ1-3(GlcNAcβ1-6)Galβ1-4GlcNAcβ-Sp8 21115 3163 515 96
4 339 GlcNAcα1-4Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Sp0 20868 9469 1575 132
5 179 GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 19530 7071 1151 94
6 172 GlcNAcα1-6Galβ1-4GlcNAcβ-Sp8 19311 4796 447 38
7 337 GlcNAcα1-4Galβ1-4GlcNAcβ-Sp0 19030 4716 883 65
8 181 GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 18737 6858 336 105
9 180 GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp8 17289 8012 1247 20
10 338 GlcNAcα1-4Galβ1-3GlcNAcβ-Sp0 16141 6376 853 106
11 341 GlcNAcα1-4Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 11672 4732 518 73
12 308 GlcNAcβ1-4GlcNAcβ-Sp10 11572 93 6 5
13 94 GalNAcβ1-3GalNAcα-Sp8 11198 450 11 5
14 340 GlcNAcα1-4Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 8758 4730 1265 175
15 88 GlcNAcβ1-3Galβ1-3GalNAcα-Sp8 8504 2809 420 24
16 182 GlcNAcβ1-3Galβ1-4Glcβ-Sp0 8464 2539 411 23
17 178 GlcNAcβ1-3Galβ-Sp8 7339 3033 307 19
18 407 GlcNAcβ1-6(GlcNAcβ1-3)GalNAcα-Sp14 6992 108 9 4
19 309 GlcNAcβ1-4GlcNAcβ-Sp12 6078 26 6 3
20 176 GlcNAcβ1-3GalNAcα-Sp8 5896 1395 49 7
21 177 GlcNAcβ1-3GalNAcα-Sp14 5782 7 7 8
22 190 GlcNAcβ1-6GalNAcα-Sp8 5571 31 7 5
23 17 GlcNAcβ-Sp8 5331 11 4 5
24 174 GlcNAcβ1-3(GlcNAcβ1-6)GalNAcα-Sp8 5309 1136 36 10
The nucleotide sequence data for Agrocybe aegerita lectin 2 will appear in the GenBank®, EMBL, DDBJ and GSDB Nucleotide Sequence Databases
under accession number JN001164.
The glycan array data of AAL-2 were deposited in the Consortium for FunctionalGlycomicsdatabase with the labels primscreen_3312–primscreen_3315.
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Figure S1 Assessment of AAL-2-binding selectivity by glycan array
A total of 465 glycans were assessed on the array (version 4.1 of the Consortium for Functional
Glycomics), and our results showed the top ten binding speciﬁc glycans of AAL-2 at 0.1 (A), 1
(B) and 50 (C)μg/ml. Results are means+ −S.E.M. The entire glycan array version is available
at http://www.functionalglycomics.org/static/consortium/resources/resourcecoreh14.shtml.
Figure S2 Effects of temperature and pH on the haemagglutination activity
of AAL-2
The haemagglutination activity of AAL-2 was tested after treatment at different temperatures (A)
(centi-degree = ◦C) and pH (B).
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Figure S3 Comparison of the AAL-2 amino acid sequence with other GlcNAc-binding lectins
TheAAL-2aminoacidsequencewasalignedwithGSL-II,WGAandHPAsequences.Thebackgroundcolourdenotessimilaritybetweenthesequences,withthedarkertheshademeaningthestronger
similarity.
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